Exelixis (EXEL) Equity Average (2011 - 2026)
Exelixis (EXEL) recorded quarterly Equity Average of $2.0 billion in Q2 2026, down 5.2% quarter-over-quarter from $2.2 billion in Q1 2026, and down 6.36% on a YoY basis from $2.2 billion in Q2 2025.
Exelixis (EXEL) Equity Average (2011 - 2026) Analysis & Trends
Exelixis' Equity Average history runs 16 years deep, the most recent figure standing at $2.0 billion for Q2 2026.
- In Q2 2026, Equity Average fell 6.36% year-over-year to $2.0 billion; the TTM figure through Apr 2026 stood at $2.0 billion (down 6.36% YoY), while the FY2026 annual figure was $2.2 billion, down 2.28% from the prior year.
- Equity Average was $2.0 billion for Q2 2026 at Exelixis, down from $2.2 billion in the prior quarter.
- In the past five years, Equity Average ranged from a high of $2.5 billion in Q2 2023 to a low of $2.0 billion in Q2 2026.
- Historically, Equity Average has averaged $2.3 billion across 5 years, with a median of $2.3 billion in 2022.
- The sharpest annual moves came in 2022 and 2024: Equity Average gained 18.84% in 2022, then fell 16.43% in 2024.
- A 5-year view of Equity Average shows it stood at $2.5 billion in 2022, then retreated by 7.4% to $2.3 billion in 2023, then slipped by 4.69% to $2.2 billion in 2024, then dropped by 4.57% to $2.1 billion in 2025, then retreated by 2.32% to $2.0 billion in 2026.
- The last three Equity Average figures came in at $2.0 billion (Q2 2026), $2.2 billion (Q1 2026), and $2.1 billion (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 516.41 Mn |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 2.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 2.05 Bn |
| Jan 2, 2026 | 2.16 Bn |
| Oct 3, 2025 | 2.10 Bn |
| Jul 4, 2025 | 2.08 Bn |
| Apr 4, 2025 | 2.19 Bn |
| Jan 3, 2025 | 2.26 Bn |
| Sep 27, 2024 | 2.20 Bn |
| Jun 28, 2024 | 2.12 Bn |
| Mar 29, 2024 | 2.20 Bn |
| Dec 29, 2023 | 2.31 Bn |
| Sep 29, 2023 | 2.44 Bn |
| Jun 30, 2023 | 2.54 Bn |
| Mar 31, 2023 | 2.52 Bn |
| Dec 30, 2022 | 2.49 Bn |
| Sep 30, 2022 | 2.44 Bn |
| Jul 1, 2022 | 2.34 Bn |
| Apr 1, 2022 | 2.25 Bn |
| Dec 31, 2021 | 2.16 Bn |
| Oct 1, 2021 | 2.08 Bn |
| Jul 2, 2021 | 1.98 Bn |